Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Erritzoe

Showing results (51-60 of 143) with videos related to

Pageof 15
Sort By:
Frontiers in Psychology|September 4, 2018
DMT Models the Near-Death ExperienceChristopher Timmermann, Leor Roseman, Luke Williams, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|January 11, 2013
Serotonin 2A receptors, citalopram and tryptophan-depletion: a multimodal imaging study of their interactions during response inhibitionJulian Macoveanu, Bettina Hornboll, Rebecca Elliott, et al.
Journal of Nuclear Medicine Technology|May 19, 2009
A probabilistic approach to delineating functional brain regionsJan Kalbitzer, Claus Svarer, Vibe G Frokjaer, et al.
Journal of Psychopharmacology (Oxford, England)|May 31, 2021
Psychedelics and health behaviour changePedro J Teixeira, Matthew W Johnson, Christopher Timmermann, et al.
Neuroimage|January 26, 2010
Brain imaging of serotonin 4 receptors in humans with [11C]SB207145-PETLisbeth Marner, Nic Gillings, Karine Madsen, et al.
Research Square|September 2, 2025
Psychedelic Therapy, Positive Emotional Experiences, and the Central Role of Self-CompassionRichard Zeifman, George Danias, Gabrielle Agin-Liebes, et al.
Nuclear Medicine and Biology|December 21, 2004
The new PET imaging agent [11C]AFE is a selective serotonin transporter ligand with fast brain uptake kineticsZhihong Zhu, Ningning Guo, Raj Narendran, et al.
The American Journal of Psychiatry|January 1, 2026
Thresholding and Perfusion Considerations in Interpreting Reduced Brain Responsiveness With Escitalopram: Response to Knudsen et alMatthew B Wall, Lysia Demetriou, Bruna Giribaldi, et al.
The American Journal of Psychiatry|May 7, 2025
Reduced Brain Responsiveness to Emotional Stimuli With Escitalopram But Not Psilocybin Therapy for DepressionMatthew B Wall, Lysia Demetriou, Bruna Giribaldi, et al.
Journal of Psychopharmacology (Oxford, England)|January 27, 2021
Brain serotonin 2A receptor binding predicts subjective temporal and mystical effects of psilocybin in healthy humansDea Siggaard Stenbæk, Martin Korsbak Madsen, Brice Ozenne, et al.
Pageof 15

Showing results (51-60 of 143) with videos related to

Sort By:
Pageof 15
Frontiers in Psychology|September 4, 2018
DMT Models the Near-Death ExperienceChristopher Timmermann, Leor Roseman, Luke Williams, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|January 11, 2013
Serotonin 2A receptors, citalopram and tryptophan-depletion: a multimodal imaging study of their interactions during response inhibitionJulian Macoveanu, Bettina Hornboll, Rebecca Elliott, et al.
Journal of Nuclear Medicine Technology|May 19, 2009
A probabilistic approach to delineating functional brain regionsJan Kalbitzer, Claus Svarer, Vibe G Frokjaer, et al.
Journal of Psychopharmacology (Oxford, England)|May 31, 2021
Psychedelics and health behaviour changePedro J Teixeira, Matthew W Johnson, Christopher Timmermann, et al.
Neuroimage|January 26, 2010
Brain imaging of serotonin 4 receptors in humans with [11C]SB207145-PETLisbeth Marner, Nic Gillings, Karine Madsen, et al.
Research Square|September 2, 2025
Psychedelic Therapy, Positive Emotional Experiences, and the Central Role of Self-CompassionRichard Zeifman, George Danias, Gabrielle Agin-Liebes, et al.
Nuclear Medicine and Biology|December 21, 2004
The new PET imaging agent [11C]AFE is a selective serotonin transporter ligand with fast brain uptake kineticsZhihong Zhu, Ningning Guo, Raj Narendran, et al.
The American Journal of Psychiatry|January 1, 2026
Thresholding and Perfusion Considerations in Interpreting Reduced Brain Responsiveness With Escitalopram: Response to Knudsen et alMatthew B Wall, Lysia Demetriou, Bruna Giribaldi, et al.
The American Journal of Psychiatry|May 7, 2025
Reduced Brain Responsiveness to Emotional Stimuli With Escitalopram But Not Psilocybin Therapy for DepressionMatthew B Wall, Lysia Demetriou, Bruna Giribaldi, et al.
Journal of Psychopharmacology (Oxford, England)|January 27, 2021
Brain serotonin 2A receptor binding predicts subjective temporal and mystical effects of psilocybin in healthy humansDea Siggaard Stenbæk, Martin Korsbak Madsen, Brice Ozenne, et al.
Pageof 15